Investor Contact Dan Ferry LifeSci Advisors 617.430.7576 daniel@lifesciadvisors.com Media Contact: The presentation will highlight how data from patients treated with IL-2 and IL-12 INDUKINE molecules in first-in-human clinical trials have successfully validated Werewolf's unique approach to engineering differentiated, tumor-activated immunotherapies. Additional details are below. Topic: Tumor-activated INDUKINE Molecules: Improving the Therapeutic Index of Proinflammatory Cytokines for Cancer Immunotherapy ...